Key result
Abstract evaluating ticagrelor versus prasugrel in STEMI patients reports no study results.
Why the study?
Despite being guideline-recommended for STEMI undergoing PCI, uncertainty remains regarding the relative efficacy of ticagrelor versus prasugrel in reducing ischemic complications.
Population
Patients with STEMI undergoing PCI
Comparison
Ticagrelor vs prasugrel
Design
Meta-analysis
Answers are grounded in this paper and cite their sources.
Meta-analysis evaluates ischemic outcomes of ticagrelor versus prasugrel in STEMI, suggesting important implications for treatment choices.
Ticagrelor and prasugrel are guideline-recommended class I antiplatelet agents for patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Despite their widespread use, there is uncertainty regarding their relative efficacy in reducing ischemic complications. This meta-analysis aims to evaluate the efficacy of ticagrelor compared with prasugrel in STEMI.
No takes yet. Share an insight, caveat, or question.
Kayani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: